Paola Rogliani

1 week ago | tandfonline.com | Elena Pistocchini |Mario Cazzola |Paola Rogliani |Luigino Calzetta

ABSTRACTIntroduction The journey from initial drug discovery to approval for respiratory diseases typically spans approximately 10.4 years and cost over $2.8 billion. This intricate process involves five stages: target identification, therapeutic molecule discovery, preclinical testing, clinical trials, and regulatory approval.

Jan 24, 2025 | resmedjournal.com | Elena Pistocchini |Mario Cazzola |Paola Rogliani

KeywordsAgeingCOPDefficacylong-acting muscarinic antagonistmeta-analysismeta-regressionsafetyIntroductionThe global elderly population is increasing rapidly, with projections indicating that individuals aged 65 and over will constitute 20% of the total population by 2030 [1]. In healthy individuals, lung development and function peak at around 25 years of age, stabilize until about 35, and then decline with aging.

Nov 21, 2024 | tandfonline.com | Mario Cazzola |Luigino Calzetta |Paola Rogliani |Maria Gabriella Matera

AbstractChronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition often complicated by cardiovascular disease (CVD) due to shared inflammatory pathways. This review explores the cardiovascular impacts of emerging anti-inflammatory therapies in COPD.

Nov 20, 2024 | dovepress.com | Paola Rogliani |Luigino Calzetta

Introduction Chronic mucus hypersecretion (CMH) in chronic obstructive pulmonary disease (COPD) is associated with a decline in forced expiratory volume in the 1st second (FEV1), increased risk for pulmonary infections, elevated frequencies of exacerbations and hospitalizations, and reduced health-related quality of life (QoL).1,2 CMH is due to altered activity of goblet and submucosal gland cells as well as decreased elimination of mucus due to altered mucociliary clearance.2 Evidence from a...

Oct 26, 2024 | resmedjournal.com | Mario Cazzola |Paola Rogliani |Maria Gabriella Matera

KeyWordsAsthmaβ-BlockersCardiovascular DiseasesFood and Drug Administration’s Adverse Event Reporting SystemReporting Odds RatioGet full text accessLog in, subscribe or purchase for full access. References1. Ora J, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. In: Martínez-García MÁ, Pépin J-L, Cazzola M, eds. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020; pp.